PURPOSE: Identification of biologically and clinically distinct breast cancer subtypes could improve prognostic assessment of primary tumors. The characteristics of "molecular" breast cancer subtypes suggest that routinely assessed histopathologic features in combination with limited biomarkers may provide an informative classification for routine use. EXPERIMENTAL DESIGN: Hierarchical cluster analysis based on components of histopathologic grade (tubule formation, nuclear pleomorphism, and mitotic score), expression of ER, cytokeratin 5/6, and HER2 amplification identified four breast cancer subgroups in a cohort of 270 cases. Cluster subgroup membership was compared with observed and Adjuvant! Online predicted 10-year survival. Survival characteristics were confirmed in an independent cohort of 300 cases assigned to cluster subgroups using a decision tree model. RESULTS: Four distinct breast cancer cluster subgroups (A-D) were identified that were analogous to molecular tumor types and showed a significant association with survival in both the original and validation cohorts (P < 0.001). There was a striking difference between survival for patients in cluster subgroups A and B with ER(+) breast cancer (P < 0.001). Outcome for all tumor types was well estimated by Adjuvant! Online, with the exception of cluster B ER(+) cancers where Adjuvant! Online was too optimistic. CONCLUSIONS: Breast cancer subclassification based on readily accessible pathologic features could improve prognostic assessment of ER(+) breast cancer.
PURPOSE: Identification of biologically and clinically distinct breast cancer subtypes could improve prognostic assessment of primary tumors. The characteristics of "molecular" breast cancer subtypes suggest that routinely assessed histopathologic features in combination with limited biomarkers may provide an informative classification for routine use. EXPERIMENTAL DESIGN: Hierarchical cluster analysis based on components of histopathologic grade (tubule formation, nuclear pleomorphism, and mitotic score), expression of ER, cytokeratin 5/6, and HER2 amplification identified four breast cancer subgroups in a cohort of 270 cases. Cluster subgroup membership was compared with observed and Adjuvant! Online predicted 10-year survival. Survival characteristics were confirmed in an independent cohort of 300 cases assigned to cluster subgroups using a decision tree model. RESULTS: Four distinct breast cancer cluster subgroups (A-D) were identified that were analogous to molecular tumor types and showed a significant association with survival in both the original and validation cohorts (P < 0.001). There was a striking difference between survival for patients in cluster subgroups A and B with ER(+) breast cancer (P < 0.001). Outcome for all tumor types was well estimated by Adjuvant! Online, with the exception of cluster B ER(+) cancers where Adjuvant! Online was too optimistic. CONCLUSIONS:Breast cancer subclassification based on readily accessible pathologic features could improve prognostic assessment of ER(+) breast cancer.
Authors: Alexander Scherrer; Ilka Schwidde; Andreas Dinges; Patrick Rüdiger; Sherko Kümmel; Karl-Heinz Küfer Journal: Health Care Manag Sci Date: 2014-10-15
Authors: Steve R Martinez; Shannon H Beal; Robert J Canter; Steven L Chen; Vijay P Khatri; Richard J Bold Journal: Med Oncol Date: 2011-09 Impact factor: 3.064
Authors: C Henry; A Quadir; N J Hawkins; E Jary; E Llamosas; D Kumar; B Daniels; R L Ward; C E Ford Journal: J Cancer Res Clin Oncol Date: 2014-09-11 Impact factor: 4.553
Authors: Lucy R Webster; Pamela J Provan; Dinny J Graham; Karen Byth; Robert L Walker; Sean Davis; Elizabeth L Salisbury; Adrienne L Morey; Robyn L Ward; Nicholas J Hawkins; Christine L Clarke; Paul S Meltzer; Rosemary L Balleine Journal: Pathology Date: 2013-12 Impact factor: 5.306